ICU ADC Override, Look-Alike Insulins, and a Sterile Compounding BUD
At a 180-bed Maryland hospital, the ICU automated dispensing cabinet (ADC) is stocked by pharmacy technicians. A nurse overrides and removes a vial labeled 'insulin aspart' from a bin that also contains 'insulin regular'; both are stored side by side because the cabinet's look-alike/sound-alike separation policy was not followed after a renovation. The nurse administers 10 units of insulin aspart instead of regular insulin. Two hours later the patient's glucose is 42 mg/dL and the patient is confused. The pharmacist is notified. Separately, the satellite pharmacy has just prepared a batch of cefazolin 2 g in 100 mL 0.9% sodium chloride and plans to assign a 7-day room-temperature beyond-use date because 'the manufacturer says the powder is stable that long.'
1. What ADC override and stocking controls should have prevented this error, and what must the pharmacist do immediately after being notified?
Read the worked answer
The ADC should have enforced LASA separation, independent double checks for high-alert medications, barcode scanning, and restricted overrides. Overrides should be limited to true emergencies, with pharmacist review as soon as possible and a report for every override. Restocking should be done by trained technicians with pharmacist verification of stock, labels, and bin locations. After notification, the pharmacist's first duty is patient care: treat the hypoglycemia per protocol, notify the provider, monitor glucose, and document. Then quarantine the remaining vials and reconfigure the ADC so insulin regular and aspart are separated and clearly labeled. Review the override log, the restocking record, and the renovation checklist. The event is a system error, not just a nurse error; blaming the nurse alone will not prevent recurrence. Notify pharmacy leadership and risk management.
2. How should the hospital handle error reporting and quality improvement, including any Maryland-specific reporting considerations?
Read the worked answer
Complete an internal incident report and a root-cause analysis. Use a just-culture approach: separate accountability for reckless behavior from system failures. Corrective actions should include physical separation of LASA products, shelf labels, ADC screen alerts, barcode scanning, override restrictions, and competency checks. Report the event through the hospital's patient-safety program and to risk management. External reporting depends on the outcome and Maryland requirements-serious harm or a sentinel event may require reporting to the appropriate state agency, and the Board may require disclosure in certain disciplinary circumstances. Do not post details on social media or discuss the patient outside the care team. Track whether similar overrides occur and audit compliance. Quality-improvement and peer-review protections may apply, but they do not excuse immediate patient disclosure and correction.
3. Evaluate the proposed 7-day room-temperature BUD for the cefazolin batch. What compounding and repackaging rules apply?
Read the worked answer
The proposed 7-day room-temperature BUD is not automatically supported by the manufacturer's powder stability. Once cefazolin is reconstituted and diluted in 0.9% sodium chloride, the BUD must be based on USP <797> requirements for the CSP category and on documented stability of the final admixture, not the powder. A default low-risk CSP has a much shorter room-temperature BUD unless the pharmacy has validated extended stability data and environmental monitoring. The batch must be prepared by qualified personnel under the correct ISO environment, with a compounding record, ingredients and lots, and a label stating the BUD and storage. If the pharmacy cannot justify 7 days, assign the shorter default BUD or refrigerate per validated data. Repackaging into syringes or other containers has separate labeling and BUD rules. The pharmacist should reject the 7-day date until the basis is documented.